Archives: Search / 2018 / 2017 / 2016 / 2015 / 2014 / 2013 / 2012


Feb 13, 2018
Interim data further support potential of ME-344 to reverse resistance to antiangiogenic therapy
Feb 8, 2018
Pipeline advancement continues, including clearance of voruciclib IND by FDA and pracinostat Orphan Drug Designation by EMA
Dec 21, 2017
New Preclinical Studies Demonstrate Repression of MCL-1 and Sensitization to BCL-2 Inhibition in Diffuse Large B-Cell Lymphoma
Nov 22, 2017
Live Webcast from San Diego on November 30th
Nov 8, 2017
Quarter highlighted by dosing of first patient in pivotal Phase 3 study of pracinostat and exclusive license agreement for voruciclib
Nov 7, 2017
Live Webcast from New York on November 15th
Sep 19, 2017
Live Webcast from New York on September 26th
Sep 5, 2017
Clinical-Stage Asset in Validated Class of Drugs with Demonstrated Value
Sep 5, 2017
Company Begins New Fiscal Year with $53.6 Million in Cash
Aug 31, 2017
Live Webcasts from Boston on September 7th and New York on September 8th
Aug 2, 2017
Randomized, double-blind, placebo-controlled study to enroll up to 500 patients worldwide
Jun 14, 2017
Two-stage study designed to evaluate tolerability and efficacy of pracinostat combined with azacitidine in patients with high and very high risk MDS